Company / Cash & Equivalents
Arcus Biosciences, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$222.0M
FY2025
5-year range
$127.0M / $222.0M
FY2021-FY2025
Trend
+48.0%
vs FY2024
Sector context
#78 of 207
Health Care
What the data says
At $222M, Arcus Biosciences, Inc.'s cash & equivalents ranks #78 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $58M in FY2019 to $222M in FY2025.
Based on SEC 10-K filings.
$222M in FY2025 with a 5-year CAGR of +5.1%.
Improved from $127M to $222M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
#78 of 207 in Health CareTop 38% of 207This company $222.0M Sector average $669.5M
▼
-66.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 48.0% year-over-year.
- Ranks #78 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $222.0M | +48.0% |
| FY2024 | $150.0M | +18.1% |
| FY2023 | $127.0M | -38.3% |
| FY2022 | $206.0M | +39.2% |
| FY2021 | $148.0M | -14.7% |
| FY2020 | $173.4M | +199.3% |
| FY2019 | $57.9M | -18.5% |
| FY2018 | $71.1M | -27.8% |
| FY2017 | $98.4M | +51.1% |
| FY2016 | $65.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026